. . . . . . . . . "\"Physostigmine Salicylate Injection should not be used in the presence of asthma, gangrene, diabetes, cardiovascular disease, mechanical obstruction of the intestine or urogenital tract or any vagotonic state, and in patients receiving choline esters and depolarizing neuromuscular blocking agents (decamethonium, succinylcholine). For post-anesthesia, the concomitant use of atropine with physostigmine salicylate is not recommended, since the atropine antagonizes the action of physostigmine.\"" . . . . . "RSA" . "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB" . "XgCzBu6OmAoYnW5UJti3l/KydcJU/LfQWrknjx9ywbjGmSXGrvoTEOY+XYeN0Mn+mg9r1qMqKIIwc8Ucj+D2zXFE9UbGY0Azu/AsjSP2glQEUtYM7Sf4Q2tahf9YQVlYefWakBMWvKmCgiEM8R7zGa6PfQ1iHWmzhCVXorj8Zd4=" . . "2021-08-25T14:32:22.426+02:00"^^ . . . . .